HOLX - Hologic
71.65
| Index: | S&P 500 | P/E: | 21.58 | EPS (ttm): | 3.32 | Insider Own: | 1.43% | Shs Outstand: | 231.72M | Perf Week: | -2.72% |
| Market Cap: | 16.46B | Forward P/E: | 15.27 | EPS next Y: | 4.69 | Insider Trans: | -4.08% | Shs Float: | 223.70M | Perf Month: | -8.19% |
| Income(ttm): | 789.50M | PEG: | 2.16 | EPS next Q: | 1.01 | Inst Own: | 103.51% | Short Float: | 2.75% | Perf Quarter: | -12.04% |
| Revenue(ttm): | 4.03B | P/S: | 4.09 | EPS this Y: | 4.68% | Inst Trans: | 2.41% | Short Ratio: | 3.53 | Perf Half Y: | -1.15% |
| Book/sh: | 22.14 | P/B: | 3.24 | EPS next Y: | 9.84% | ROA: | 8.63% | Short Interest: | 6.15M | Perf Year: | 1.89% |
| Cash/sh: | 10.16 | P/C: | 7.06 | EPS next 5Y: | 10.00% | ROE: | 15.56% | 52W Range: | 70.24 - 84.67 | Perf YTD: | 0.28% |
| Dividend Est.: | - | P/FCF: | 14.26 | EPS past 5Y: | - | ROI: | 10.22% | 52W High: | -15.38% | Beta: | 0.98 |
| Dividend TTM: | - | Quick Ratio: | 3.03 | Sales past 5Y: | 6.10% | Gross Margin: | 55.53% | 52W Low: | 2.01% | ATR (14): | 1.69 |
| Dividend Ex-Date: | - | Current Ratio: | 3.69 | EPS Y/Y TTM: | 81.34% | Oper. Margin: | 24.07% | RSI (14): | 29.71 | Volatility: | 2.23% 2.17% |
| Employees: | 7063 | Debt/Eq: | 0.52 | Sales Y/Y TTM: | -0.00% | Profit Margin: | 19.59% | Recom: | 2.30 | Target Price: | 87.62 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.51 | EPS Q/Q: | 106.46% | Payout: | 0.00% | Rel Volume: | 4.91 | Prev Close: | 70.76 |
| Sales Surprise: | 0.99% | EPS Surprise: | -0.32% | Sales Q/Q: | 4.51% | Earnings: | Nov 04 AMC | Avg Volume: | 1.74M | Price: | 71.65 |
| SMA20: | -5.52% | SMA50: | -8.73% | SMA200: | -7.84% | Undervalued: 22.29% | Volume: | 8,560,791 | Change: | 1.26% | |
Graham Classic formula value: 84.96
(P/E=8 * 1g) Min value: 53.66
(current P/E * 2g) Max value: 123.96
Average value: 87.53
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women's health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.